The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1299
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Advertisements for TNF Inhibitors

Some tumor necrosis factor (TNF) inhibitors are being promoted on the internet directly to the public for use in psoriasis (www.yahoo.com).

EFFECTIVENESS — In one study, the percentage of patients with moderate-to-severe psoriasis treated with etanercept 50 mg twice weekly who improved 75% in psoriasis area severity index (PASI) score was 49% at 12 weeks and 59% at 24 weeks.1 About 75% of patients treated with infliximab achieved a 75% reduction in PASI score after 3 injections over a 10-week period.2 In a 52- week multicenter study of 1212 patients randomized to receive adalimumab (40 mg) or placebo every other week, 71% (578 of 814) of adalimumab-treated and 7% (26 of 398) of placebo-treated patients had achieved >75% improvement in the PASI score by week ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1299
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian